儿童慢性乙型肝炎的诊治现状及进展  

Advance on diagnosis and treatment in children with chronic hepatitis B

作　　者：张敏[1] 朱世殊[1] ZHANG Min;ZHU Shi-shu(Pediatric Liver Disease Therapy and Research Center,302 Military Hospital of China,Beijing 100039,China)

机构地区：[1]解放军第三〇二医院青少年肝病诊疗与研究中心,北京100039

出　　处：《传染病信息》2018年第3期231-236,共6页Infectious Disease Information

基　　金：2016首度特色基金课题(Z161100000516176)

摘　　要：对慢性乙型肝炎儿童进行抗病毒治疗可以阻止肝脏炎症、纤维化的进展,部分可以达到临床治愈。应选择免疫清除期、再活动期进行治疗,出现疾病进展、严重并发症时也应治疗。目前儿童可及抗病毒药物有干扰素、核苷(酸)类似物。其中,干扰素是治疗的一线药物,核苷(酸)类似物是二线用药,联合使用效果值得期待。合理选择适应证进行个体化治疗才能使患儿获益最大化。Antiviral therapy in children with chronic hepatitis B(CHB)can prevent the progression of liver inflammation and fibrosis,and some of these pediatric patients can be clinically cured.The treatment should start at the period of immune clearance and reactivity,either when the disease progresses or serious complications occur.Currently,interferon and nucleoside analogues can be available for antiviral therapy in children.IFN is a first-line agent for treatment.Nucleoside(acid)analogues(NA)are second-line agents,and the combination of IFN and NA produces potential effects.To maximize the benefit of antiviral therapy in children with CHB,it is vital that to choose the adaptive indication and give individualized treatment.

关 键 词：儿童 慢性乙型肝炎 抗病毒治疗 干扰素 核苷(酸)类似物 

分 类 号：R511.7[医药卫生—内科学]